Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Novartis has reported a robust operational performance in its third quarter of 2024, reflecting a continuation of positive trends over the past two years.</li><li>The company announced a 10% growth in sales and a 20% increase in core operating income in constant currencies.</li><li>Notably, the core margin reached 40.1%.</li></ul>

Novartis has reported a robust operational performance in its third quarter of 2024, reflecting a continuation of positive trends over the past two years.The company announced a 10% growth in sales and a 20% increase in core operating income in constant currencies.Notably, the core margin reached 40.1%.

Novartis AG: Cardiovascular Disease Portfolio Expansion As A Critical Growth Catalyst! - Major Drivers

<ul><li>Novartis's second quarter 2024 earnings were decent and revealed a company strongly positioned and confident of its continued growth trajectory.</li><li>From a financial standpoint, the Swiss multinational pharmaceutical firm posted a solid performance with 11% quarter-on-quarter growth in sales, profits expanding 19%, and a core margin of 39.6%.</li><li>The robustness in financials was driven by commendable productivity as well as sustained sales growth.</li></ul>

Novartis's second quarter 2024 earnings were decent and revealed a company strongly positioned and confident of its continued growth trajectory.From a financial standpoint, the Swiss multinational pharmaceutical firm posted a solid performance with 11% quarter-on-quarter growth in sales, profits expanding 19%, and a core margin of 39.6%.The robustness in financials was driven by commendable productivity as well as sustained sales growth.

Novartis AG (NVS): Acquisition of Mariana Oncology for Expansion of Oncology Portfolio

Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>After two rejections, Mesoblast has finally received FDA approval for its first drug. Celltrion has received FDA approval for its Stelara biosimilar, which will be launched in February 2025.</li>
<li>Peptidream has become eligible for a milestone payment. Sumitomo Pharma is strengthening R&amp;D for regenerative medicine and cell therapy business. Astellas Pharma in-licenses technology for developing neurology drugs.</li>
<li>Hansoh Pharmaceutical granted an exclusive global license to Merck for its pre-clinical drug candidate. Lupin received FDA approval to market generic version of blockbuster Descovy tablets.</li>
</ul>


After two rejections, Mesoblast has finally received FDA approval for its first drug. Celltrion has received FDA approval for its Stelara biosimilar, which will be launched in February 2025.
Peptidream has become eligible for a milestone payment. Sumitomo Pharma is strengthening R&amp;D for regenerative medicine and cell therapy business. Astellas Pharma in-licenses technology for developing neurology drugs.
Hansoh Pharmaceutical granted an exclusive global license to Merck for its pre-clinical drug candidate. Lupin received FDA approval to market generic version of blockbuster Descovy tablets.


APAC Healthcare Weekly (Dec 22)- Mesoblast, Celltrion, Peptidream, Astellas, Hansoh, Lupin

<ul><li>In Q1 2024, Novartis delivered robust growth, reflecting in a double-digit sales growth and core margin expansion.</li><li>Sales were up by 11% in constant currency, and core operating income was up by 22%.</li><li>The core margin reached 38.4%, inching steadily towards the set goal of over 40% by 2027.</li></ul>

In Q1 2024, Novartis delivered robust growth, reflecting in a double-digit sales growth and core margin expansion.Sales were up by 11% in constant currency, and core operating income was up by 22%.The core margin reached 38.4%, inching steadily towards the set goal of over 40% by 2027.

Novartis AG: Positive Expectations for Scemblix & 5 Other Major Developments

<ul><li>Based on the earnings call transcript from the Q4 2023 Novartis, the company delivered a strong full-year performance with margin expansion and strong momentum in innovation with 10 positive Phase III results over the course of the year.</li><li>The company recorded a 10% growth in Q4 sales and core operating income up by 13%.</li><li>For the full year, the sales were up by 10% and core operating income up by 18%, all in constant currency.</li></ul>

Based on the earnings call transcript from the Q4 2023 Novartis, the company delivered a strong full-year performance with margin expansion and strong momentum in innovation with 10 positive Phase III results over the course of the year.The company recorded a 10% growth in Q4 sales and core operating income up by 13%.For the full year, the sales were up by 10% and core operating income up by 18%, all in constant currency.

Novartis AG: Can The Acquisition of MorphoSys AG Really Strengthen  Its Oncology Pipeline? - Major Drivers

Switzerland

Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company uses innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis offers patent protected prescription medicine and generic pharmaceuticals and biosimilars.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Novartis (NOVN SW)

Novartis AG: Cardiovascular Disease Portfolio Expansion As A Critical Growth Catalyst! - Major Drivers

Novartis has reported a robust operational performance in its third quarter of 2024, reflecting a continuation of positive trends over the past...

Baptista Research

Novartis AG (NVS): Acquisition of Mariana Oncology for Expansion of Oncology Portfolio

Novartis's second quarter 2024 earnings were decent and revealed a company strongly positioned and confident of its continued growth...

Baptista Research

APAC Healthcare Weekly (Dec 22)- Mesoblast, Celltrion, Peptidream, Astellas, Hansoh, Lupin

Mesoblast got FDA approval for its first drug, while Betta Pharma, Celltrion, and Lupin also received some major FDA approvals. Pharma companies...

Tina Banerjee

Novartis AG: Positive Expectations for Scemblix & 5 Other Major Developments

In Q1 2024, Novartis delivered robust growth, reflecting in a double-digit sales growth and core margin expansion. Sales were up by 11% in...

Baptista Research

Novartis AG: Can The Acquisition of MorphoSys AG Really Strengthen Its Oncology Pipeline? - Major Drivers

Based on the earnings call transcript from the Q4 2023 Novartis, the company delivered a strong full-year performance with margin expansion and...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)